Merck/Moderna cancer vaccine cuts risk of death or recurrence from melanoma by over 40%

3

Oct 22 (Reuters) – An mRNA cancer vaccine developed by Moderna and Merck in combination with a widely used immunotherapy cut the risk of death or recurrence of melanoma by 42% and disease spread by

(The article has been published through a syndicated feed. Except for the headline, the content has been published verbatim. Liability lies with original publisher.)